Pharma channel feed

Bio­gen has a shaky end to H1 with a $542M write-off adding to its woes — but an­a­lysts see big rev­enue ahead for Aduhelm

4 years ago

Bio­gen de­fends slow roll­out of new Alzheimer's drug, crit­i­cizes neg­a­tive me­dia at­ten­tion

4 years ago

Mer­ck, Ei­sai notch full ap­proval for Keytru­da-TKI in­hibitor com­bo in ad­vanced en­dome­tri­al can­cer

4 years ago
FDA+

In­side Bio­gen's scram­ble to sell Aduhelm: Project 'Javelin' and pres­sure to ID as many pa­tients as pos­si­ble

4 years ago

In 60 days, most in­sur­ers will be re­quired to cov­er HIV pre­ven­tion drugs and re­lat­ed ser­vices with no cost-shar­ing

4 years ago
FDA+

How cozy is too cozy? FDA and Bio­gen of­fer up a test case

4 years ago
FDA+

FDA re­jects pro­fes­sor’s pe­ti­tion seek­ing to pull ‘dan­ger­ous’ Ot­su­ka kid­ney dis­ease drug

4 years ago
FDA+

Terms of mega opi­oid set­tle­ment set to be dis­closed this week — re­port

4 years ago

Mer­ck KGaA for­ti­fies its ‘site of the fu­ture’ with $319M re­search, staff train­ing cen­ters

4 years ago

FDA’s do­mes­tic bio­phar­ma in­spec­tions re­turn to nor­mal as agency faces back­log of 8,000+

4 years ago
FDA+

As­traZeneca earns an­oth­er ap­proval in jam-packed Chi­nese PD-(L)1 mar­ket, this time in late-stage lung can­cer

4 years ago
China

Re­gen­eron, al­ready an in­sti­tu­tion in NY, earns Cuo­mo's back­ing for a $1.8B ex­pan­sion at Tar­ry­town hive

4 years ago
Financing

Bris­tol My­ers Squibb takes an­oth­er late-stage loss for Op­di­vo-Yer­voy com­bo in head and neck can­cer

4 years ago
R&D

Pfiz­er set­tles EpiPen price hike law­suits for $345M

4 years ago

Safe­ty con­cerns push FDA ad­comm to vote over­whelm­ing­ly against ap­proval for Fi­bro­Gen ane­mia drug

4 years ago
FDA+

Ma­jor health sys­tems refuse to ad­min­is­ter Aduhelm as top FDA lead­ers meet be­hind closed doors to talk with pay­ers

4 years ago
FDA+

FDA chides Am­gen over mis­lead­ing ban­ner ad for Neu­las­ta

4 years ago
FDA+

FDA mulls reg­u­la­to­ry ac­tion on Sprout's 'fe­male Vi­a­gra' af­ter ad­verse events spike

4 years ago
FDA+

In re­ver­sal, em­ploy­ers, union groups push for Con­gress to al­low Medicare to ne­go­ti­ate drug prices

4 years ago

House com­mit­tees kick off in­ves­ti­ga­tion in­to how Bio­gen's Aduhelm won ap­proval

4 years ago
FDA+

CMS kicks off 9-month process on whether to lim­it cov­er­age to Bio­gen's new Alzheimer's drug

4 years ago

Biden sets a 45-day count­down for 'com­pre­hen­sive' plan to tack­le drug pric­ing — while cham­pi­oning some fa­mil­iar poli­cies

4 years ago

Astel­las and Seagen's Pad­cev wins full FDA ap­proval, notch­ing ex­pand­ed la­bel in tough-to-crack urothe­lial can­cer

4 years ago
FDA+

Bay­er takes SGLT2 hope­fuls head on with FDA ap­proval for new kid­ney dis­ease drug

4 years ago
FDA+
First page Previous page 236237238239240241242 Next page Last page
A service from the Financial Times